1.Liu X*, Chen L*, Liu C, Mei Z, Li J, Zhang Y, Chang M, Zhang H, Guo C, Zhang M, An G, Yang J, Chen W, Xue Y, Zhang C, Ni M, Zhang Y. Percutaneous coronary intervention as an independent predictor of non-target lesion progression in 1658 patients with coronary artery disease. Theranostics. 2026 Jan 14;16(7):3857-3869.
2. Li J, Chen L, Liu X,Zhang M#,Liu X#.Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments. Semin Cancer Biol. 2025 Sep 23;116:108-120.
3. Guo C*,Liu X*,Mei Z, Chang M, Li J, Wang B, Ji W, Zhang M, Zhang M, Zhang C, An G. AMBP protects against aortic valve calcification by inhibiting ERK1/2 and JNK pathways mediated by FHL3. Theranostics. 2025 Mar 18;15(10):4398-4415.(并列第一作者)
4. Guo CH, Wang QQ, Li JQ, Ji W, Chen L, Chang ML, Ma LY,Liu XL#, Ni M#. BMP1 inhibitor UK383367 improves MI-induced cardiac remodeling and fibrosis in mice via ameliorating macrophage polarization and mitochondrial dysfunction. Acta Pharmacol Sin. 2025 Sep 2.(共同通讯)
5. Mei Z, Guo C, Yang H, Li J, Chang M, Zhang C, Ni M, Chen L, Gao W,Liu X#, An G#. Serum Alpha-1-microglobulin (A1M) as an independent predictor of calcific aortic valve stenosis and its diagnostic value. Int J Cardiol. 2025 Aug 6:133706.(共同通讯)
6. Li J, Chang M, Mei Z, Zhu Q, Yue X, Zhang M,Li M#,Liu X#. Female Fabry Patient With Left Ventricular Outflow Tract Obstruction. JACC Case Rep. 2025;30(4):102702.
7. Ma L, Chen L, Li J, Wang Q, Liu X,Liu X#, Zhang Y#, Ni M#. Arrhythmogenic cardiomyopathy mimicking cardiac amyloidosis with Waldenström macroglobulinaemia: A diagnostic challenge. ESC Heart Fail. 2025 Nov 3.(共同通讯)
8. Ma J*,Liu X*, Qiao L, Meng L, Xu X, Xue F, Cheng C, Han Z, Lu Y, Zhang W, Bu P, Zhang M, An G, Lu H, Ni M, Zhang C, Zhang Y. Association Between Stent Implantation and Progression of Nontarget Lesions in a Rabbit Model of Atherosclerosis. Circ Cardiovasc Interv. 2021 Nov;14(11):e010764.(并列第一作者)
9. Liu X*, Ma J*, Ma L, Liu F, Zhang C, Zhang Y, Ni M. Overexpression of tissue factor induced atherothrombosis in apolipoprotein E-/- mice via both enhanced plaque thrombogenicity and plaque instability. J Mol Cell Cardiol. 2019;127:1‐10.
10. Ma J, Qiao L, Meng L, Ma L, Zhao Y,Liu XL*, Ni M*, Zhang Y. Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip. Biomed Pharmacother. 2019;113:108767.(共同通讯)
11.Liu XL*, Ni M*, Ma L*, Yang J, Wang L, Liu F, Dong M, Yang X, Zhang M, Lu H, Wang J, Zhang C, Jiang F, Zhang Y. Targeting blood thrombogenicity precipitates atherothrombotic events in a mouse model of plaque destabilization. Sci Rep. 2015;5:10225.
12.Liu XL, Zhang PF, Ding SF, Wang Y, Zhang M, Zhao YX, Ni M, Zhang Y. Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice. PLoS One. 2012;7(3):e33497.
13.Ding SF*, Ni M*, Liu XL*, Qi LH, Zhang M, Liu CX, Wang Y, Lv HX, Zhang Y. A causal relationship between shear stress and atherosclerotic lesions in apolipoprotein E knockout mice assessed by ultrasound biomicroscopy. Am J Physiol Heart Circ Physiol, 2010;298(6):H2121-2129.(并列第一作者)
14. Zhang M, Liu Y, Xu M, Zhang L, Liu Y,Liu X, Zhao Y, Zhu F, Xu R, Ou Z, Wang Y, Liu Q, Ma S, Wang T, He M, Lu Q, Li H, Huang J, Zhang Y. Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study. Sci Rep. 2019 Mar 14;9(1):4545.